Clinical Trial Update: Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers aged 2-71 months (potentially st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Pneumococcal Disease
• Pneumococcal Disease
• Streptococcus Pneumoniae Diseases

Drugs mentioned

• 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13)

Snippet

Sponsor: Walvax Biotechnology Co., Ltd. | Conditions: Diseases Caused by Streptococcus Pneumoniae Serotypes | Phase 3 | Status: COMPLETED